Arvinas at the Piper Sandler Healthcare Conference
Today, we share exciting news from Arvinas, Inc. With a commitment to pioneering therapeutic advances, Arvinas will actively participate in the Piper Sandler 37th Annual Healthcare Conference. This important event will take place in a renowned city, allowing leading minds in the healthcare sector to discuss the latest innovations.
Fireside Chat Details
Join Arvinas’ Chief Medical Officer, Noah Berkowitz, M.D., Ph.D., and Chief Financial Officer, Andrew Saik, in a revealing fireside chat. They'll delve into how Arvinas is revolutionizing the treatment landscape. The chat is scheduled for December 4 at 11:00 a.m. ET, promising insights into the company's vision and strategic goals.
Understanding Arvinas’ Mission
Arvinas, Inc. (Nasdaq: ARVN) stands at the forefront of biopharmaceutical innovation, focusing on targeted protein degradation. This novel approach, termed PROTAC (PROteolysis TArgeting Chimera), harnesses the body's natural processes to eliminate disease-exacerbating proteins. The company is dedicated to crafting therapies that not only target symptoms but aim to address the disease's root causes.
Ongoing Clinical Programs
With multiple compelling investigational drugs in its pipeline, Arvinas is making great strides in clinical development. Key agents include:
- ARV-102, aimed at LRRK2 to provide new hope for neurodegenerative diseases.
- ARV-393, designed to tackle BCL6 in relapsed/refractory non-Hodgkin lymphoma.
- ARV-806, a targeted approach for KRAS G12D mutations, which are notoriously challenging in pancreatic and colorectal cancers.
- Vepdegestrant, focusing on the estrogen receptor to benefit patients battling locally advanced or metastatic ER+/HER2- breast cancer.
Innovation at Arvinas
Arvinas continues to harness the power of science and innovation. The company's research integrates cutting-edge discoveries to empower patients with debilitating conditions. By targeting disease-causing proteins effectively, Arvinas seeks to enhance treatment efficacy and patient outcomes. Their commitment to addressing complex challenges in medicine highlights their leadership in the biotechnology sector.
Company Engagement and Communication
For those interested in following Arvinas’ journey, additional information can be found on their official website. Moreover, social media platforms like LinkedIn and X (formerly Twitter) keep the public updated with real-time insights and developments.
Connecting with Arvinas
Strong communication channels are essential, and Arvinas offers contact points for interested investors and media representatives. For inquiries related to investments, reach out to Jeff Boyle at +1 (347) 247-5089 or via email at Jeff.Boyle@arvinas.com. For media queries, contact Kirsten Owens at +1 (203) 584-0307 or email at Kirsten.Owens@arvinas.com. These contacts facilitate open dialogue about the company's impactful work.
Frequently Asked Questions
What is the focus of Arvinas, Inc.?
Arvinas is dedicated to the development of therapies using targeted protein degradation to combat various diseases.
When will Arvinas present at the healthcare conference?
The company will present at the Piper Sandler Healthcare Conference on December 4 at 11:00 a.m. ET.
What are the key drugs in Arvinas' pipeline?
Notable investigational drugs include ARV-102 for neurodegenerative disorders and ARV-393 for non-Hodgkin lymphoma.
How can I stay updated on Arvinas' activities?
You can visit their official website and follow them on LinkedIn and X for the latest updates.
Who should I contact for media inquiries about Arvinas?
Media representatives can reach out to Kirsten Owens for inquiries related to Arvinas.